Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors-Reference-Cited by-同舟云学术

Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors

Published:2023-10-18 Issue:1 Volume:30 Page:116-126
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Hayashi Takahiro¹²^ORCID,Tateishi Kensuke¹²³^ORCID,Matsuyama Shinichiro¹²^ORCID,Iwashita Hiromichi⁴^ORCID,Miyake Yohei¹²^ORCID,Oshima Akito¹²^ORCID,Honma Hirokuni¹²^ORCID,Sasame Jo¹²^ORCID,Takabayashi Katsuhiro¹²^ORCID,Sugino Kyoka¹²³^ORCID,Hirata Emi¹²^ORCID,Udaka Naoko⁵^ORCID,Matsushita Yuko⁶^ORCID,Kato Ikuma⁷^ORCID,Hayashi Hiroaki²⁸^ORCID,Nakamura Taishi¹²⁹^ORCID,Ikegaya Naoki¹^ORCID,Takayama Yutaro¹²^ORCID,Sonoda Masaki¹²^ORCID,Oka Chihiro¹²^ORCID,Sato Mitsuru¹^ORCID,Isoda Masataka¹²^ORCID,Kato Miyui²³^ORCID,Uchiyama Kaho²³^ORCID,Tanaka Tamon¹²^ORCID,Muramatsu Toshiki¹²^ORCID,Miyake Shigeta¹^ORCID,Suzuki Ryosuke¹¹⁰^ORCID,Takadera Mutsumi¹¹¹²^ORCID,Tatezuki Junya¹¹^ORCID,Ayabe Junichi¹²^ORCID,Suenaga Jun¹^ORCID,Matsunaga Shigeo¹³^ORCID,Miyahara Kosuke¹⁴^ORCID,Manaka Hiroshi¹⁵^ORCID,Murata Hidetoshi¹^ORCID,Yokoyama Takaakira¹⁶^ORCID,Tanaka Yoshihide¹²^ORCID,Shuto Takashi¹³^ORCID,Ichimura Koichi⁶^ORCID,Kato Shingo¹⁷^ORCID,Yamanaka Shoji⁵^ORCID,Cahill Daniel P.¹⁸^ORCID,Fujii Satoshi⁵⁷^ORCID,Shankar Ganesh M.¹⁸^ORCID,Yamamoto Tetsuya¹^ORCID

Affiliation:

1. 1Department of Neurosurgery, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.

2. 2Neurosurgical-Oncology Laboratory, Yokohama City University, Yokohama, Japan.

3. 3Laboratory of Biopharmaceutical and Regenerative Science, Graduate School of Medical Science, Yokohama City University, Yokohama, Japan.

4. 4Department of Pathology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.

5. 5Department of Diagnostic Pathology, Yokohama City University Hospital, Yokohama, Japan.

6. 6Department of Brain Disease Translational Research, Juntendo University Faculty of Medicine, Tokyo, Japan.

7. 7Department of Molecular Pathology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.

8. 8Department of Pediatrics, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.

9. 9Department of Neurosurgery, Yokohama City University Medical Center, Yokohama, Japan.

10. 10Department of Neurosurgery, Odawara Municipal Hospital, Odawara, Japan.

11. 11Department of Neurosurgery, Yokohama City Minato Red Cross Hospital, Yokohama, Japan.

12. 12Department of Neurosurgery, Yokosuka Kyosai Hospital, Yokosuka, Japan.

13. 13Department of Neurosurgery, Yokohama Rosai Hospital, Yokohama, Japan.

14. 14Department of Neurosurgery, National Hospital Organization Yokohama Medical Center, Yokohama, Japan.

15. 15Department of Neurosurgery, Yokohama Minami Kyosai Hospital, Yokohama, Japan.

16. 16Department of Neurosurgery, Hiratsuka Kyosai Hospital, Hiratsuka, Japan.

17. 17Department of Clinical Cancer Genomics, Yokohama City University, Yokohama, Japan.

18. 18Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Abstract

Abstract Purpose: The 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors uses an integrated approach involving histopathology and molecular profiling. Because majority of adult malignant brain tumors are gliomas and primary CNS lymphomas (PCNSL), rapid differentiation of these diseases is required for therapeutic decisions. In addition, diffuse gliomas require molecular information on single-nucleotide variants (SNV), such as IDH1/2. Here, we report an intraoperative integrated diagnostic (i-ID) system to classify CNS malignant tumors, which updates legacy frozen-section (FS) diagnosis through incorporation of a qPCR-based genotyping assay. Experimental Design: FS evaluation, including GFAP and CD20 rapid IHC, was performed on adult malignant CNS tumors. PCNSL was diagnosed through positive CD20 and negative GFAP immunostaining. For suspected glioma, genotyping for IDH1/2, TERT SNV, and CDKN2A copy-number alteration was routinely performed, whereas H3F3A and BRAF SNV were assessed for selected cases. i-ID was determined on the basis of the 2021 WHO classification and compared with the permanent integrated diagnosis (p-ID) to assess its reliability. Results: After retrospectively analyzing 153 cases, 101 cases were prospectively examined using the i-ID system. Assessment of IDH1/2, TERT, H3F3AK27M, BRAFV600E, and CDKN2A alterations with i-ID and permanent genomic analysis was concordant in 100%, 100%, 100%, 100%, and 96.4%, respectively. Combination with FS and intraoperative genotyping assay improved diagnostic accuracy in gliomas. Overall, i-ID matched with p-ID in 80/82 (97.6%) patients with glioma and 18/19 (94.7%) with PCNSL. Conclusions: The i-ID system provides reliable integrated diagnosis of adult malignant CNS tumors.

Funder

Japan Society for the Promotion of Science

Strategic Research Promotion of Yokohama City University Research

Yokohama Foundation for Advanced Medical Science

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-1660/3373547/ccr-23-1660.pdf

Reference45 articles.

1. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016;Ostrom;Neuro Oncol,2019